Nigella Sativa Supplementation in Hyperlipidemia Treatment
Launched by ISTANBUL BILGI UNIVERSITY · Mar 21, 2025
Trial Information
Current as of April 23, 2025
Completed
Keywords
ClinConnect Summary
This research, which is a randomized controlled intervention study, was conducted between June 2023 and February 2024 with adult individuals with a BMI\>25 kg/m2 who applied to the Cardiology Polyclinic of Karamürsel State Hospital and were referred to a nutrition and diet specialist after being diagnosed with hyperlipidemia according to AHA criteria by the physician.
Sample Selection and Randomization The sample size of the study was calculated using the G-Power 3.1.9 analysis program with a medium effect size (d=0.60), 90% power, α: 0.05 and 1-β: 0.95, with a minimum of 32 people in each...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults individuals who were diagnosed hyperlipidemia
- • Individuals suitable for taking Nigella satvia supplement
- • Individuals BMI\>25 kg/m2
- Exclusion Criteria:
- • Chronic liver disease,
- • Chronic kidney disease,
- • Heart failure, infarction or cerebrovascular disease,
- • Pregnant and breastfeeding women,
- • Severe psychiatric disorders,
- • Oncological diseases,
- • Individuals using medications that could interact with black seed oil (anticoagulant, antihypertensive, etc.)
- • Individuals using antilipidemic or anticholesterolemic medications
- • Individuals did not do heavy exercise
- • Individuals using any nutritional supplement
- • Individuals have a known history of allergy
- • Individuals did not consume alcohol regularly
- • Individuals with special dietary needs
Trial Officials
Hande Seven Avuk, PhD
Principal Investigator
İstanbul Bilgi University
About Istanbul Bilgi University
Istanbul Bilgi University is a prominent educational and research institution in Turkey, dedicated to advancing knowledge across various disciplines, including health sciences. With a commitment to excellence in research and innovation, the university actively engages in clinical trials aimed at enhancing healthcare outcomes. By fostering collaborations with healthcare professionals and leveraging its academic expertise, Istanbul Bilgi University strives to contribute to the development of effective medical interventions and evidence-based practices, ultimately improving patient care and advancing public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
İstanbul, , Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported